MyPeBS addresses the crucial and timely question of the future of breast cancer screening in Europe. Indeed current standard mammographic screening, with entry stratified by age alone, has recently been largely questioned. Despite a demonstrated mean 20% reduction in breast cancer-specific mortality, together with reduction of late-stage disease in women older than 50, it is associated with potential harms including false positive recalls and over-diagnosis. Individual breast cancer risk estimation, through models including clinical variables, mammographic breast density and more than 100 genetic polymorphisms, now has substantial clinical and scientific bases. Personalized screening strategies, based on individual risk levels, could potentially improve the individual benefit/harms ratio of screening (earlier cancer detection and less intensive treatments in high risk women, less false positives and over-diagnoses in low risk ones), and increase the cost-efficacy for health insurances. MyPEBS will conduct an international randomized phase III trial to validate this hypothesis. It will primarily assess the ability of an individual risk-based screening strategy to be non-inferior, and possibly superior, to the standard of care screening, in reducing the cumulative incidence of stage II+ breast cancers. The trial, conducted in 5 countries (France, Italy, UK, Belgium and Israel) will include 85000 European women aged 40-70, all followed for 4 years. MyPEBS will also evaluate if an individual risk-based screening strategy, compared with the standard, reduces screening-related harms (unnecessary biopsies, overdiagnoses) in low-risk women, is overall at least as cost-effective as well as more accepted by women resulting in a larger screening coverage. After analyses of all components, the final objective of MyPEBS is to deliver recommendations for the best future breast cancer screening strategy in Europe.

The 'Fostering Oncology Research by Charities in Europe' consortium (FORCE) is a network of 15 European charities across 12 European countries joining forces to support pragmatic clinical trials tackling high and unmet medical needs in oncology in Europe. The main objective of the FORCE CSA is to provide the Mission Board with an ambitious, yet feasible, programme by & for cancer charities, to optimize their contribution to the Europe’s Beating Cancer Plan. The Pragmatic Clinical Trial Programme will be elaborated in a bottom-up coordinated approach, involving all relevant stakeholders (researchers and professionals from different disciplines, patients, citizens, policy makers and regulatory authorities) across Member States and Associated Countries. During the CSA, the FORCE consortium will propose foundational pillars for EU strategic support to a European cancer charities network dedicated to organising, implementing and monitoring sustainable and ambitious support for cancer pragmatic clinical trials. The overall objectives of this initiative are to: 1. Define and deliver a Pragmatic Clinical Trial Programme by cancer charities; 2. Implement two transnational calls to test and improve our proposed programme (feasibility step); 3. Deliver to the EC a blueprint on pragmatic oncology clinical trials by charities to facilitate decision-making and provide guidelines for the future work programme. Through the successful achievement of these objectives, the FORCE network will both strengthen cooperation among European cancer charities and mobilise the European research community through crucial scientific questions to improve health outcomes for cancer patients through patient-focused research. This action is part of the Cancer Mission cluster of projects on "Diagnostics and treatment".

Cancer is a worldwide health burden and a major public health challenge. Despite significant advances in the understanding, prevention, diagnostics and treatment, cancer remains a public health problem in Europe and the world. In such a setting, translational cancer research plays a key role in successfully addressing the growing burden of cancer. The great potential of translational cancer research in Europe will only be achieved when the main barriers are systematically addressed through concerted actions between public and private organisations that provide funds for research, researchers, healthcare providers and all those engaged in the cancer research spectrum. Moreover, adequate and systematic financial support backed by a strong political commitment is absolutely essential to help reduce the burden of cancer that European citizens are currently facing. In this context, the TRANSCAN-3 network, with a strong background in funding cancer research, embodies an excellent model of cross-national cooperation by bringing together 31 funding organisations, from 20 countries, with the common goal of supporting high-impact translational cancer research through cross-national joint calls for proposals, and by an efficient investment of dedicated national/regional public funding, leveraged with foundation/charity-based resources and EU financial support. Building up on the well-established cooperation and accomplishments, through the harmonisation of national/regional funding mechanisms and programmes, plus continued and sustained series of efforts for the access to and sharing of data on cancer research, this TRANSCAN-3 project also aims at becoming a catalysts for a sustainable model of funding of high-impact cancer research in Europe and beyond, with an approach to effectively engage relevant stakeholders (patients, society as a whole, policy makers, etc.) in different stages of the action.